ZURAMPIC is a URAT1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.

The use of Zurampic is contraindicated in the presence of severe renal impairment, end stage renal disease, tumor lysis syndrome, Lesch-Nyhan syndrome and in kidney transplant recipients, and patients on dialysis.

Criteria for Approval

1) Patient must have a diagnosis of symptomatic chronic gout; AND

2) Inadequate response to xanthine oxidase inhibitor therapy, including ONE of the following at the maximum medically appropriate dosages:
   a. allopurinol (Zyloprim)
   b. febuxostat (Uloric)
   AND

3) Must be used in combination with xanthine oxidase inhibitor; AND

4) Patient must have an estimated creatinine clearance (eCrCl) greater than 45 mL/min

Continuation Criteria

1) Clinical documentation indicating an improvement in symptoms; AND

2) Continued use of a xanthine oxidase inhibitor; AND

3) Estimated creatinine clearance (eCrCl) greater than 45 mL/min

References

1.) Lexi-Comp drug monograph for Zurampic (Reviewed 2/27/2017)
2.) Zurampic package insert (1/2016)